Loading clinical trials...
Loading clinical trials...
A Phase III, Double-blind, Placebo-controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention- Deficit/Hyperactivity Disorder (ADHD)
Conditions
Interventions
Lisdexamfetamine dimesylate (LDX)
Placebo
Locations
51
United States
Peninsula Research Associates, Inc.
Rolling Hills Estates, California, United States
Miami Research Associates
South Miami, Florida, United States
Vince and Associates Clinical Research
Overland Park, Kansas, United States
CNS Healthcare
Memphis, Tennessee, United States
ZNA Antwerpen, Commandant Weynsstraat 165
Hoboken, Antwerpen, Belgium
Afdeling Psychiatrie, UZ Herestraat 49
Leuven, Flemish Brabant, Belgium
Start Date
January 27, 2009
Primary Completion Date
October 26, 2011
Completion Date
October 26, 2011
Last Updated
June 9, 2021
NCT07478458
NCT07465081
NCT07314333
NCT07189442
NCT06711224
NCT06221358
Lead Sponsor
Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions